PFG Investments LLC Cuts Stake in Hologic, Inc. (NASDAQ:HOLX)

PFG Investments LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,268 shares of the medical equipment provider’s stock after selling 214 shares during the quarter. PFG Investments LLC’s holdings in Hologic were worth $591,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in shares of Hologic during the third quarter valued at $29,000. NBC Securities Inc. purchased a new stake in shares of Hologic during the third quarter valued at $33,000. Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Hologic during the fourth quarter valued at $33,000. Deseret Mutual Benefit Administrators grew its holdings in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 155 shares during the last quarter. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Hologic by 163.9% during the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 341 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Raymond James upped their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. UBS Group upped their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Needham & Company LLC upped their price target on shares of Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 2nd. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $86.89.

Hologic Trading Up 1.5 %

Shares of Hologic stock opened at $77.35 on Thursday. The firm has a market capitalization of $18.16 billion, a PE ratio of 36.66, a P/E/G ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The firm’s 50-day moving average price is $74.73 and its 200 day moving average price is $71.84. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue was down 5.7% on a year-over-year basis. During the same period last year, the company posted $1.07 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insider Transactions at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock worth $2,473,443 in the last 90 days. Insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.